Adenylosuccinic Acid: An Orphan Drug with Untapped Potential.

Pharmaceuticals (Basel)

Institute for Health and Sport (IHeS), Victoria University, Melbourne, VIC 8001, Australia.

Published: May 2023

Adenylosuccinic acid (ASA) is an orphan drug that was once investigated for clinical application in Duchenne muscular dystrophy (DMD). Endogenous ASA participates in purine recycling and energy homeostasis but might also be crucial for averting inflammation and other forms of cellular stress during intense energy demand and maintaining tissue biomass and glucose disposal. This article documents the known biological functions of ASA and explores its potential application for the treatment of neuromuscular and other chronic diseases.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10304260PMC
http://dx.doi.org/10.3390/ph16060822DOI Listing

Publication Analysis

Top Keywords

adenylosuccinic acid
8
orphan drug
8
acid orphan
4
drug untapped
4
untapped potential
4
potential adenylosuccinic
4
acid asa
4
asa orphan
4
drug investigated
4
investigated clinical
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!